The U.S. Food and Drug Administration (FDA) has published a new batch of draft Product-Specific Guidances (PSGs) aimed at supporting the development of generic medicines and improving the pathway for Abbreviated New Drug Applications (ANDAs).
The announcement, published on August 21, 2026, highlights the agency’s continued efforts to facilitate generic drug development, streamline regulatory assessment, and expand access to high-quality, therapeutically equivalent alternatives to approved brand-name medicines.
Advancing Access to Affordable Medicines Through Regulatory Guidance
FDA Product-Specific Guidances provide recommendations for pharmaceutical developers on how to demonstrate that generic versions of approved medicines meet the required standards for safety, effectiveness, and quality.
According to the agency, these guidances help reduce uncertainty during generic drug development and support a more efficient review process for ANDAs.
The latest publication includes a total of 55 PSGs, consisting of 24 new guidances and 31 revised guidances. More than 30 of the guidances address products with no currently approved ANDAs, including several complex drug products.
Oncology Therapies Included in New Guidance Package
Among the products covered in this latest batch are targeted oncology therapies, reflecting FDA’s continued focus on supporting precision medicine approaches in cancer treatment.
The new guidances include targeted oral kinase inhibitors approved for specific types of non-small cell lung cancer (NSCLC). These therapies represent an important area of modern oncology, where molecular alterations guide treatment selection and improve outcomes for selected patient populations.
The inclusion of these medicines in FDA’s generic drug development framework may help support future availability of additional therapeutic options while maintaining strict standards for quality and effectiveness.
Focus on Complex Medicines and Innovative Treatments
The latest PSG package includes 18 guidances for complex drug products, including seven new and 11 revised guidances.
Complex products often require specialized approaches to demonstrate therapeutic equivalence because of their unique characteristics, formulations, or mechanisms of action.
The FDA also highlighted guidances related to other important therapies, including a first-in-class dipeptidyl peptidase 1 (DPP1) inhibitor for non-cystic fibrosis bronchiectasis and a poly (ADP-ribose) polymerase (PARP) inhibitor associated with biomarker-driven cancer treatment.
PARP inhibitors have become a key component of precision oncology, particularly in cancers associated with BRCA mutations, where treatment strategies are guided by specific genomic alterations.
Supporting the Future of Generic Drug Development
The newly released guidances also include recommendations supported by research funded through the Generic Drug User Fee Amendments (GDUFA) program.
Examples include updated recommendations for ferumoxytol injection and new guidance for benzoyl peroxide and tretinoin topical cream, providing alternative approaches for demonstrating bioequivalence.
The FDA noted that once finalized, these PSGs will represent the agency’s current recommendations for developing generic drug products that are therapeutically equivalent to their reference listed drugs.
A Step Toward Greater Treatment Accessibility
By expanding guidance for generic versions of complex and specialized medicines, the FDA aims to encourage competition, improve availability, and support broader patient access to essential therapies.
For oncology, where innovative treatments often come with significant costs, regulatory pathways that enable high-quality generic development may play an important role in improving long-term accessibility to critical medicines.
More articles like this are available on OncoDaily.